0 results for "3002150010"
SUPERCHEMIBLOCK HETEROPHILE BLOCKING AGENT IT IS A HIGHLY PURIFIED IMMUNOGLOBULINS WITH PROPRIETARY AUGMENTING REAGENTS, A NON-STERILE LIQUID
REAGENT RED BLOOD CELL PRODUCT CONSISTING OF BLOOD FRACTION OF HUMAN ORIGIN FOR USE IN ANTIBODY DETECTION THE PRODUCT IS PRESENTED IN 3 VIALS
A REAGENT RED BLOOD CELL PRODUCT CONSISTING OF BLOOD FRACTION OF HUMAN ORIGIN FOR USE IN ANTIBODY DETECTION THE PRODUCT IS PRESENTED IN 1 X 10ML VIALS
A REAGENT RED BLOOD CELL PRODUCT CONSISTING OF BLOOD FRACTION OF HUMAN ORIGIN FOR USE IN ANTIBODY DETECTION THE PRODUCT IS PRESENTED IN A 10ML VIAL
SOLIRIS IS A THERAPY SPECIFICALLY TESTED AND APPROVED FOR THE TREATMENT OF PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH), AN ULTRA-RARE, LIFE-THREATENING BLOOD DISORDER. SOLIRIS HAS BEEN APPROVED FOR THE TREATMENT OF PATIENTS WITH PNH IN NEARLY 50 COUNTRIES WORLDWIDE. SOLIRIS 300 MG/30ML IS A FORMULATION OF ECULIZUMAB WHICH IS A RECOMBINANT HUMANIZED MONOCLONAL IGG2/4;κ ANTIBODY PRODUCED BY MURINE MYELOMA CELL CULTURE AND PURIFIED BY STANDARD BIOPROCESS TECHNOLOGY. ECULIZUMAB CONTAINS HUMAN CONSTANT REGIONS FROM HUMAN IMMUNOGLOBULIN G2 SEQUENCES AND HUMAN IMMUNOGLOBULIN G4 SEQUENCES AND MURINE COMPLEMENTARITY-DETERMINING REGIONS GRAFTED ONTO THE HUMAN FRAMEWORK LIGHT- AND HEAVY-CHAIN VARIABLE REGIONS. ECULIZUMAB IS COMPOSED OF TWO 448 AMINO ACID HEAVY CHAINS AND TWO 214 AMINO ACID LIGHT CHAINS AND HAS A MOLECULAR WEIGHT OF APPROXIMATELY 148 KDA. SOLIRIS 300 MG/30ML IS A STERILE, CLEAR, COLORLESS, PRESERVATIVE-FREE SOLUTION FOR INTRAVENOUS INFUSION AND IS SUPPLIED IN 30-ML SINGLE-USE VIALS. THE PRODUCT IS FORMULATED AT PH 7 AND EACH VIAL CONTAINS 300 MG OF ECULIZUMAB, 13.8 MG SODIUM PHOSPHATE MONOBASIC, 53.4 MG SODIUM PHOSPHATE DIBASIC, 263.1 MG SODIUM CHLORIDE, 6.6 MG POLYSORBATE 80 (VEGETABLE ORIGIN) AND WATER FOR INJECTION. THE FP IS SUPPLIED IN VIALS AS DESCRIBED ABOVE.